Despite advancements in the treatment, ovarian cancer-related mortality has been relatively constant for over 30 years. With currently available therapy which includes cytoreductive or debulking surgery followed by platinum-drug-based chemotherapy, ovarian cancer detected at stage I has a survival rate of 94%. Cytoreductive surgery is an “optimal” surgery that leaves not larger than 2 cm tumor inside the body as a suggestive measure to minimize the surgery-related complications with patient’s conditions. Platinum containing chemotherapeutic drugs like taxane help eradicate the residual portion of the tumor. Detection of ovarian cancer at later (metastasis) stages (III and IV) reduces the survival chance to 35% even though patients are well treated. This is because of relapse of the disease in 15% of the patients which is mostly incurable. Ovarian cancer often gives non-specific symptoms, which makes it difficult to screen at an early stage of the disease. Strategies to evaluate biomarkers that help in diagnosing cancer at stage I or II and also in the prognosis of the relapse of the disease in the post-hospitalized patients would enable a better survival chance of the patients. The most popular diagnostic mechanism is transvaginal or pelvic ultrasound followed by serum detection of cancer antigen 125 (CA125) also known as Mucin 16 (MUC16), which is a high molecular weight cell surface-associated glycoprotein (Scholler et al. 2006). Unfortunately, only 35% of patients can be screened for stage I cancer using the combined methods. CA125 is a reliable marker for monitoring the response of treatment and disease recurrence, rather than for early diagnosis. During the past decade numerous biomarkers, independently or in conjunction with CA125, were clinically evaluated for their cancer-associated over-expression, and their expression in normal and cancerous OSE cell lines was verified using immunohistochemical procedures. Claudin-3 and -4 are the tight junction epithelial surface protein associated with increased invasiveness and metalloproteinase-II activity in OEC, and they served as suitable markers alternate to CA125 to monitor recurrence of the disease in patients non-responsive to chemotherapy (Litkouhi et al. 2007). B7-H4, an immunomodulatory protein, is another CA125 independent biomarker highly expressed in ovarian cancer tissues compared to the normal tissues (Simon et al. 2007). Serum cytokines, notably epidermal growth factor (EGF), monocyte chemotactic protein-1 (MCP-1), vascular endothelial growth factor (VEGF) tumor necrosis factor-α (TNF- α), and interleukin-6 and -8 are the batches of inflammatory markers that respond to stage I of OEC and enhance the CA125 diagnostic sensitivity (Lambeck et al. 2007). These inflammatory compounds also up-regulate the anti-inflammatory c-reactive proteins (CRP), and in situations of metastasis, this marker is correlated with the spread of cancer to other tissues (Hefler et al. 2008). Another batch of about 24 cancer-associated proteins was evaluated successfully as blood markers of OEC. These included WAP four-disulfide core domain 2 (WFDC2), Mesothelin (MSLN), insulin-like growth factor-2 (IGF-2), Chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1) etc. In combination with CA125, these marker